Chardan Capital Reaffirms “Buy” Rating for Sonnet BioTherapeutics (NASDAQ:SONN)
Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Chardan Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $20.00 price objective on the stock. Sonnet BioTherapeutics Stock Up 4.2 % SONN stock opened at $1.25 on Monday. Sonnet BioTherapeutics has a […]
Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Chardan Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $20.00 price objective on the stock. Sonnet BioTherapeutics Stock Up 4.2 % SONN stock opened at $1.25 on Monday. Sonnet BioTherapeutics has a […]